NASDAQ:ESLA Estrella Immunopharma (ESLA) Stock Price, News & Analysis → No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free (From Hedgeye) (Ad) Free ESLA Stock Alerts $0.98 +0.08 (+9.01%) (As of 10:49 AM ET) Add Compare Share Share Today's Range$0.88▼$1.0150-Day Range$0.88▼$1.2652-Week Range$0.86▼$33.00Volume5,547 shsAverage Volume31,174 shsMarket Capitalization$35.65 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsOwnershipSEC FilingsShort InterestTrends Get Estrella Immunopharma alerts: Email Address Ad Paradigm PressTime is Running Out - June 25th Deadline Approaching!Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.That will slam shut June 25. About Estrella ImmunopharmaEstrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.Read More ESLA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ESLA Stock News HeadlinesMay 20, 2024 | investorplace.comESLA Stock Earnings: Estrella Immunopharma Reported Results for Q3 2024March 7, 2024 | finance.yahoo.comEntheon Biomedical Corp. (ENTBD)February 1, 2024 | msn.comEstrella Immunopharma Approves $1 Million Stock Buyback ProgramJanuary 17, 2024 | msn.comWhy DatChat Shares Are Trading Lower By Around 33%; Here Are 20 Stocks Moving PremarketNovember 23, 2023 | uk.investing.comEstrella Immunopharma Inc (ESLA)November 3, 2023 | finance.yahoo.comEstrella Immunopharma, Inc. (ESLA)November 1, 2023 | morningstar.comEstrella Immunopharma Inc ESLAOctober 20, 2023 | finance.yahoo.comWe Think Estrella Immunopharma (NASDAQ:ESLA) Can Afford To Drive Business GrowthSee More Headlines Receive ESLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Estrella Immunopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/10/2024Fiscal Year End6/30/2024Next Earnings (Estimated)8/13/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ESLA CUSIPN/A CIK1844417 Webwww.estrellabio.com Phone510-318-9098FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-80,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-151.17% Return on Assets-26.43% Debt Debt-to-Equity RatioN/A Current Ratio62.34 Quick Ratio62.34 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($8.27) per share Price / Book-0.11Miscellaneous Outstanding Shares36,380,000Free Float16,333,000Market Cap$32.71 million OptionableNot Optionable Beta0.16 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Cheng Liu Ph.D. (Age 57)CEO, President & Director Jiandong XuChief Financial OfficerKey CompetitorsSangamo TherapeuticsNASDAQ:SGMOOmega TherapeuticsNASDAQ:OMGAbluebird bioNASDAQ:BLUEAthira PharmaNASDAQ:ATHADBV TechnologiesNASDAQ:DBVTView All Competitors ESLA Stock Analysis - Frequently Asked Questions How have ESLA shares performed in 2024? Estrella Immunopharma's stock was trading at $1.11 at the beginning of 2024. Since then, ESLA shares have decreased by 11.7% and is now trading at $0.98. View the best growth stocks for 2024 here. Are investors shorting Estrella Immunopharma? Estrella Immunopharma saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 9,200 shares, a decrease of 18.6% from the April 30th total of 11,300 shares. Based on an average trading volume of 27,600 shares, the short-interest ratio is currently 0.3 days. Approximately 0.1% of the company's shares are short sold. View Estrella Immunopharma's Short Interest. When is Estrella Immunopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our ESLA earnings forecast. How were Estrella Immunopharma's earnings last quarter? Estrella Immunopharma, Inc. (NASDAQ:ESLA) posted its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.01) earnings per share for the quarter. How do I buy shares of Estrella Immunopharma? Shares of ESLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ESLA) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTrump convicted... now what?Unexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTime is Running Out - June 25th Deadline Approaching!Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRIL...Paradigm Press | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
